The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.

@article{Sfikakis2010TheFD,
  title={The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.},
  author={Petros P. Sfikakis},
  journal={Current directions in autoimmunity},
  year={2010},
  volume={11},
  pages={180-210}
}
Results from clinical trials of biologic anti-TNF drugs performed in the late 1990s confirmed the biological relevance of TNF function in the pathogenesis of chronic noninfectious inflammation of joints, skin and gut, which collectively affects 2-3% of the population. Up to April 2009, more than two million patients worldwide have received the first marketed drugs, namely the monoclonal anti-TNF antibodies infliximab and adalimumab and the soluble TNF receptor etanercept. All three are equally… CONTINUE READING